Foghorn Therapeutics (FHTX) Operating Margin (2020 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly Operating Margin of 660.33% in Q1 2026, down 155.72% quarter-over-quarter from 258.22% in Q4 2025, and down 27537.0% on a YoY basis from N/an in Q1 2025.
Foghorn Therapeutics (FHTX) Operating Margin (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Operating Margin history runs 7 years deep, the most recent figure standing at 660.33% for Q1 2026.
- In Q1 2026, Operating Margin fell 27537.0% year-over-year to 660.33%; the TTM figure through Mar 2026 stood at 301.34% (up 11307.0% YoY), while the FY2025 annual figure was 279.49%, up 17481.0% from the prior year.
- Operating Margin was 660.33% for Q1 2026 at Foghorn Therapeutics, down from 258.22% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 97.73% in Q3 2023 to a low of 840.51% in Q4 2024.
- Historically, Operating Margin has averaged 481.59% across 5 years, with a median of 441.29% in 2023.
- The sharpest annual moves came in 2022 and 2024: Operating Margin jumped 6362525 bps in 2022, then plunged 39922 bps in 2024.
- A 5-year view of Operating Margin shows it stood at 762.09% in 2022, then surged by 42 bps to 441.29% in 2023, then sank by 90 bps to 840.51% in 2024, then soared by 69 bps to 258.22% in 2025, then slumped by 156 bps to 660.33% in 2026.
- The last three Operating Margin figures came in at 660.33% (Q1 2026), 258.22% (Q4 2025), and 226.92% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | -660.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -660.33% |
| Dec 31, 2025 | -258.22% |
| Sep 30, 2025 | -226.92% |
| Jun 30, 2025 | -279.17% |
| Mar 31, 2025 | -384.96% |
| Dec 31, 2024 | -840.51% |
| Sep 30, 2024 | -305.48% |
| Jun 30, 2024 | -386.64% |
| Mar 31, 2024 | -558.30% |
| Dec 31, 2023 | -441.29% |
| Sep 30, 2023 | -97.73% |
| Jun 30, 2023 | -572.42% |
| Mar 31, 2023 | -627.56% |
| Dec 31, 2022 | -762.09% |
| Sep 30, 2022 | -425.97% |
| Jun 30, 2022 | -650.07% |
| Mar 31, 2022 | -709.29% |
| Dec 31, 2021 | -3,938.57% |
| Sep 30, 2021 | -64,051.22% |
| Jun 30, 2021 | -8,337.28% |